NEDC e-Bulletin Editor’s Note Welcome to the 60th edition of the NEDC e-Bulletin.
Read moreYoung people go through periods of great change biologically, physically and psychologically.
Read moreAfter over six months of consultation with the eating disorders community and wider health sector, NEDC has published a consultation report which outlines our findings.
Read moreGlucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes.
Read more